phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs, compound, pharmaceutical composition, method for increasing cognition in a patient in whom such an increase is desired, method of treating a patient suffering from degeneration or decline in cognition, method for the treatment of a patient who has a disease involving reduced levels of camp, method of inhibiting the activity of the enzyme pde4 in a patient, method of treatment of a patient suffering from memory degeneration due to a neurodegenerative disease, method of treatment of a patient suffering from memory degeneration due to an acute neurodegenerative disorder, method of treating a patient suffering from an allergic or inflammatory disease, method of treating a patient suffering from schizophrenia, method of treating a patient who suffers from psychosis characterized by high levels of pd4, and said psychosis is a form of depression depression

摘要

"PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS, COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INCREASING COGNITION IN A PATIENT WHICH IS SUCH INCREASED OF A MEDIUM OR A DETAILED PATIENT FOR THE TREATMENT OF A PATIENT WHO HAS A DISEASE INVOLVING REDUCED CAMP LEVELS, METHOD OF INHIBITING THE PDE4 ENZYME ACTIVITY IN A PATIENT, METHOD OF TREATING A PATIENT DEVELOPMENT OF THE DEVELOPMENT OF THE MALE DEVELOPMENT OF A PATIENT SUFFERING FROM MEMORY DEGENERATION DUE TO ACUTE NEURODEGENERATIVE DISORDER, METHOD OF TREATMENT OF A PATIENT SUFFERING FROM AN ALLERGIC OR INFLAMMATORY DISEASE SUFFERING FROM PSYCHOSIS CHARACTERIZED BY HIGH LEVELS PDE4, THE DIET PSYCHOSIS IS A F DEMAND OF DEPRESSION ". Inhibition of PDFA is achieved by novel compounds, for example N-substituted diarylamine analog. The compounds of the present invention are of formula (I), wherein A, B, D, R¬1¬, R¬2¬, R¬3¬ and R¬4¬ are as defined herein.